I agree that this site is using cookies. You can find further informations here.
X
Lattanzi, Maria
597  results:
Search for persons X
?
1

Sustained antibody persistence for at least 15 years after ..:

Beran, Jiří ; Lattanzi, Maria ; Costantini, Marco..
Vaccine.  41 (2023)  23 - p. 3518-3524 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Fully Liquid MenACWY-CRM Vaccine: Results from an Integrate..:

Vir Singh, Puneet ; Tiberi, Paola ; Di Domenico, Gabriele Filippo...
Drug Safety.  46 (2022)  1 - p. 99-108 , 2022
Link: https://doi.org/10.1007/..
 
?
3

632. Clinical Experience with a New Fully Liquid Presentati..:

Díez-Domingo, Javier ; Vandermeulen, Corinne ; Akhund, Tauseefullah...
Open Forum Infectious Diseases.  8 (2021)  Supplement_1 - p. S419-S420 , 2021
Link: https://doi.org/10.1093/..
 
?
4

A new fully liquid presentation of MenACWY-CRM conjugate va..:

Vandermeulen, Corinne ; Leroux-Roels, Isabel ; Vandeleur, James...
Vaccine.  39 (2021)  45 - p. 6628-6636 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Immunological non-inferiority of a new fully liquid present..:

Díez-Domingo, Javier ; Tinoco, Juan Carlos ; Poder, Airi...
Human Vaccines & Immunotherapeutics.  18 (2021)  1 - p. , 2021
Link: https://doi.org/10.1080/..
 
?
6

Safety and immunogenicity of an investigational maternal tr..:

Swamy, Geeta K. ; Metz, Torri D. ; Edwards, Kathryn M....
Vaccine.  38 (2020)  44 - p. 6930-6940 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Safety and immunogenicity of fully liquid and lyophilized f..:

Beran, Jiri ; Leroux-Roels, Geert ; Van Damme, Pierre...
Vaccine.  38 (2020)  16 - p. 3227-3234 , 2020
Link: https://doi.org/10.1016/..
 
?
8

Second five-year follow-up after a booster vaccination agai..:

Beran, Jiri ; Lattanzi, Maria ; Xie, Fang..
Vaccine.  37 (2019)  32 - p. 4623-4629 , 2019
Link: https://doi.org/10.1016/..
 
?
9

MenACWY-CRM conjugate vaccine booster dose given 4–6 years ..:

Tipton, Mary ; Daly, Wendy ; Senders, Shelly...
Vaccine.  37 (2019)  42 - p. 6171-6179 , 2019
Link: https://doi.org/10.1016/..
 
?
10

A phase I, randomized, controlled, dose-ranging study of in..:

Leroux-Roels, Geert ; Lattanzi, Maria ; Solis, Claudia Dovali...
Human Vaccines & Immunotherapeutics.  14 (2017)  1 - p. 45-58 , 2017
Link: https://doi.org/10.1080/..
 
?
11

Evaluation of rabies immunogenicity and tolerability follow..:

Jelinek, Tomas ; Cramer, Jakob P. ; Dieckmann, Sebastian...
Travel Medicine and Infectious Disease.  13 (2015)  3 - p. 241-250 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pan..:

Knuf, Markus ; Leroux-Roels, Geert ; Rümke, Hans. C....
Vaccine.  33 (2015)  1 - p. 174-181 , 2015
Link: https://doi.org/10.1016/..
 
?
13

A randomised, single-blind, dose-range study to assess the ..:

Hatz, Christoph ; Cramer, Jakob P. ; Vertruyen, André...
Vaccine.  30 (2012)  32 - p. 4820-4827 , 2012
Link: https://doi.org/10.1016/..
 
?
14

A randomized clinical trial to identify the optimal antigen..:

Hatz, Christoph ; von Sonnenburg, Frank ; Casula, Daniela..
Vaccine.  30 (2012)  23 - p. 3470-3477 , 2012
Link: https://doi.org/10.1016/..
 
?
15

Assessment of the immunogenicity and safety of varying dose..:

Fukase, Hiroyuki ; Furuie, Hidetoshi ; Yasuda, Yuji...
Vaccine.  30 (2012)  33 - p. 5030-5037 , 2012
Link: https://doi.org/10.1016/..
 
1-15